John H. Stone
Harvard University
Internal medicineSurgeryPathologyAntibodyDermatologyImmunologyAnti-neutrophil cytoplasmic antibodyVasculitisGiant cell arteritisTocilizumabPrednisoneMicroscopic polyangiitisDiseaseIgG4-related diseaseFibrosisRituximabGranulomatosis with polyangiitisPopulationMedicineGastroenterology
536Publications
94H-index
29.3kCitations
Publications 533
Newest
#1Sharon A. Chung (UCSF: University of California, San Francisco)H-Index: 22
#2Mark Gorelik (Columbia University)H-Index: 1
Last. Peter C. Grayson (NIH: National Institutes of Health)H-Index: 25
view all 32 authors...
OBJECTIVE To provide evidence-based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN). METHODS Twenty-one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for systemic, non-hepatitis B-related PAN. Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodo...
Source
#1Mehrdad Maz (KU: University of Kansas)H-Index: 6
#2Sharon A. Chung (UCSF: University of California, San Francisco)H-Index: 22
Last. Peter C. Grayson (NIH: National Institutes of Health)H-Index: 25
view all 32 authors...
OBJECTIVE To provide evidence-based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. METHODS Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendation...
1 CitationsSource
#1Sharon A. Chung (UCSF: University of California, San Francisco)H-Index: 22
#2Carol A. Langford (Cleveland Clinic)H-Index: 41
Last. Peter C. Grayson (NIH: National Institutes of Health)H-Index: 25
view all 32 authors...
OBJECTIVE To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). METHODS Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic ...
1 CitationsSource
#2Manu Shankar-Hari (Guy's and St Thomas' NHS Foundation Trust)H-Index: 32
#3C L Vale (UCL: University College London)H-Index: 1
Last. Gabriel Baron (University of Paris)H-Index: 55
view all 67 authors...
Importance: Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm. Objective: To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes. Data Sources: Trials were identified through systematic searches of electronic databases between October 2020 and January 2021. Searches were not restricted by trial st...
5 CitationsSource
#1Marco Lanzillotta (UniSR: Vita-Salute San Raffaele University)H-Index: 16
#2Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 27
Last. Gabriele Capurso (UniSR: Vita-Salute San Raffaele University)H-Index: 56
view all 10 authors...
Abstract null null Background null Type I autoimmune pancreatitis (AIP) and IgG4-related sclerosing cholangitis (IgG4-SC) belong to the IgG4-related disease (IgG4-RD) spectrum. Both entities respond to glucocorticoids, but iatrogenic toxicity associated with prolonged steroid therapy and relapse represent relevant clinical concerns in the long-term. Rituximab is increasingly used as an effective alternative strategy to induce remission but data regarding the safety and efficacy of B-cell depleti...
Source
#1P Jane McDowell ('QUB': Queen's University Belfast)H-Index: 2
#2John H. Stone (Harvard University)H-Index: 94
Last. Liam G Heaney ('QUB': Queen's University Belfast)H-Index: 58
view all 9 authors...
Reduction in glucocorticoid exposure is the primary benefit of new biologic treatments in severe asthma, but there is currently no evidence that reduction in glucocorticoid exposure corresponds to a proportionate reduction in associated toxicity. OBJECTIVES To use the validated Glucocorticoid Toxicity Index (GTI) to assess change in glucocorticoid toxicity after 12 months treatment with mepolizumab, and compare toxicity change to glucocorticoid reduction and change in patient reported outcome me...
Source
#1Eric A. Meyerowitz (Montefiore Medical Center)H-Index: 8
#2Pritha Sen (Harvard University)H-Index: 9
Last. Cig
view all 8 authors...
In SARS-CoV-2 infection, the viral load peaks early setting off a cascade of immune dysregulation that persists well after viral clearance. Severe COVID-19 is marked by aberrant innate and adaptive immune responses with an abnormal cytokine profile and a prolonged illness course with multisystem organ dysfunction. Antiviral treatments have yet to show benefit later in critical illness. Taken together, this raises the concern that a purely antiviral treatment approach may be insufficient. A numbe...
7 CitationsSource
#1Mark Matza (Harvard University)H-Index: 3
#2Ana D. Fernandes (Harvard University)H-Index: 3
Last. Sebastian Unizony (Harvard University)H-Index: 18
view all 4 authors...
OBJECTIVE: To evaluate the efficacy and safety of ustekinumab (UST) in giant cell arteritis (GCA). METHODS: We conducted a prospective, open-label trial of UST in patients with active new-onset or relapsing GCA. Active disease was defined as the presence of GCA symptoms and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) elevation within 6 weeks of baseline. All patients received a 24-week prednisone taper and subcutaneous UST 90mg at baseline, weeks 4, 12, 20, 28, 36 and 44. Th...
14 CitationsSource
Source
Source